What is the official website of BENU Farmacia ?

The official website of BENU Farmacia is http://www.benufarma.it.

What is BENU Farmacia's cybersecurity risk score?

BENU Farmacia has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has BENU Farmacia experienced?

According to Rankiteo, BENU Farmacia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has BENU Farmacia been affected by any supply chain cyber incidents ?

According to Rankiteo, BENU Farmacia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does BENU Farmacia have SOC 2 Type 1 certification ?

According to Rankiteo, BENU Farmacia is not certified under SOC 2 Type 1.

Does BENU Farmacia have SOC 2 Type 2 certification ?

According to Rankiteo, BENU Farmacia does not hold a SOC 2 Type 2 certification.

Does BENU Farmacia comply with GDPR ?

According to Rankiteo, BENU Farmacia is not listed as GDPR compliant.

Does BENU Farmacia have PCI DSS certification ?

According to Rankiteo, BENU Farmacia does not currently maintain PCI DSS compliance.

Does BENU Farmacia comply with HIPAA ?

According to Rankiteo, BENU Farmacia is not compliant with HIPAA regulations.

Does BENU Farmacia have ISO 27001 certification ?

According to Rankiteo,BENU Farmacia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does BENU Farmacia operate in ?

BENU Farmacia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does BENU Farmacia have ?

BENU Farmacia employs approximately 813 people worldwide.

Does BENU Farmacia own any subsidiaries ?

BENU Farmacia presently has no subsidiaries across any sectors.

How many LinkedIn followers does BENU Farmacia have ?

BENU Farmacia's official LinkedIn profile has approximately 35,270 followers.

What is the NAICS classification code for BENU Farmacia ?

BENU Farmacia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does BENU Farmacia have a Crunchbase profile ?

No, BENU Farmacia does not have a profile on Crunchbase.

Does BENU Farmacia have a LinkedIn profile ?

Yes, BENU Farmacia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/admenta-italia-s-p-a-benufarmacia.

How many cybersecurity incidents has BENU Farmacia experienced ?

As of June 19, 2026, Rankiteo reports that BENU Farmacia has not experienced any cybersecurity incidents.

How many peer or competitor companies does BENU Farmacia have ?

BENU Farmacia has an estimated 5,692 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

BENU Farmacia

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

BENU Farmacia Vendor Cyber Rating & Cyber Score

benufarma.it

Add Your Compliance Badge

ADMENTA Italia S.p.A., gruppo PHOENIX, è leader della distribuzione farmaceutica al dettaglio e intermedia in Italia. ADMENTA Italia conta oltre 1.400 tra dipendenti e collaboratori e sviluppa un giro d’affari complessivo di oltre 600 milioni di Euro; gestisce oltre 320 punti vendita tra farmacie e parafarmacie, sia di proprietà che in Franchising. ADMENTA Italia si propone infatti come partner privilegiato per il farmacista indipendente che desidera affiliarsi alla rete di Farmacie BENU.

BENU Farmacia A.I CyberSecurity Scoring

Scoring History

BENU Farmacia

BENU Farmacia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

BENU Farmacia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for BENU Farmacia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for BENU Farmacia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for BENU Farmacia in 2026.

Incident Types BENU Farmacia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for BENU Farmacia in 2026.

Incident History - BENU Farmacia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

BENU Farmacia Subsidiaries

BENU Farmacia

Pharmaceutical Manufacturing

Website: http://www.benufarma.it

Company Size: 1,001-5,000 employees

PHOENIX group - Integrated Healthcare ProviderWholesale

Gruppo ComifarTransportation, Logistics, Supply Chain and Storage

NomecoTransportation, Logistics, Supply Chain and Storage

Apotek 1Pharmaceutical Manufacturing

FarmeximWholesale Drugs and Sundries

OCP PortugalWholesale

PHOENIX Pharma BulgariaPharmaceutical Manufacturing

PHX IrelandPharmaceutical Manufacturing

Help Net FarmaPharmaceutical Manufacturing

Tamro FinlandWholesale

Tamro BalticsPharmaceutical Manufacturing

Tamro SwedenPharmaceutical Manufacturing

SmilaHospitals and Health Care

PHOENIX Pharma ItaliaWholesale

PHOENIX Medical Supplies LtdPharmaceutical Manufacturing

PHOENIX FarmacijaPharmaceutical Manufacturing

PHOENIX Pharmahandel GmbH & Co KGWholesale

EL PHARMA – PHOENIX group Representation ServicesHealth and Human Services

Kemofarmacija d.d.Wholesale

PHOENIX Zdravotnícke zásobovanie, a.s.Wholesale

PHOENIX BelgiumHospitals and Health Care

BENU BelgiumPharmaceutical Manufacturing

BENU SlovenskoPharmaceutical Manufacturing

PHOENIX Pharma Switzerland AGHealth and Human Services

SOFIADISWholesale

Pharmacies BENU SAPharmaceutical Manufacturing

Loading…

BENU Farmacia Similar Companies

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

BENU Farmacia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56078

SUMMARY

PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-56077

SUMMARY

PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56076

SUMMARY

PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:N

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.8

REFERENCES

CVE-2026-56075

SUMMARY

PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-56074

SUMMARY

PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…